Hyperprogression and hypercalcemia after nivolumab treatment in three cases with renal cell carcinoma.
Burcu CanerHulya ErtasBirol OcakErdem CubukcuPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2022)
The development of hypercalcemia may help predict hyperprogression in patients with renal cell carcinoma who receive immunotherapy. In such cases, early evaluation of progression and cessation of nivolumab may be considered.